Turnaround Time:10-12 Business Days
The view that all estrogens are ‘bad’ and cause cancer is a simplistic one. Estradiol (E2) and estrone (E1) are metabolised into at least 14 different species. These breakdown products and have their own specific biological actions; some have the stimulatory properties of estradiol whilst others are weak and antagonistic to other estrogen molecules. An imbalance of the stimulatory versus weak estrogen metabolites have been observed to be associated with many different health disorders. Whilst high levels of the 16α-hydroxyestrone stimulatory estrogen raise cancer risk, lower levels are associated with osteoporosis. In contrast, if the weak estrogens are high they protect against cancer but inhibit bone growth. Therefore the estrogen metabolites are not inactive excretion products but powerful molecules in their own right and should be monitored.
- Hot flushes
- Irregular menstruation
- Bone loss
- Dry skin
- Elevated estrogens
- Gynaecological cancer history or family history
NOTICE TO PATIENTS
NutriPATH practices in the usual practitioner-referral system for pathology laboratories. Patients are highly recommended to seek the supervision and guidance of a qualified healthcare practitioner for the interpretation of any lab results and associated information. NutriPATH can offer assistance in locating a suitable practitioner.